Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead (GILD) to Acquire HOOK for $10 million Gilead ...

Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to acquire some of its assets for a total consideration of up to $10M.

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Friends of the Village recently announced there will be 10 farmers markets in Mount Gilead this year, beginning Saturday, May 31, and continuing through Oct. 4. The first market will be on Saturday, ...

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.